Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
Trial Details
- NCT ID
- NCT07171528
- Phase
- PHASE2
- Sponsor
- National Cancer Center, Korea
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- Secondary Cytoreductive Surgery
- Locations (sample)
- Goyang-si, Gyeonggi-do, South Korea|37.65639,126.835
Key Eligibility Criteria
- Patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Patients with recurrent ovarian cancer who have received platinum-based chemotherapy (3 or 4 cycles) and were deemed unsuitable for secondary cytor…
- Patients with recurrent ovarian cancer who have responded to chemotherapy (Complete Response, Partial Response, or Stable Disease).
- The patient's disease must have recurred after platinum-based therapy, and be defined as platinum-sensitive, meaning progression occurred more than…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →